Drug Profile
TPI 526
Alternative Names: TPI-526Latest Information Update: 24 May 2010
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Anti-inflammatories
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 19 Oct 2006 Phase-I clinical trials in Inflammation in USA (PO)